SC
INZY

Samlyn Capital’s Inozyme Pharma INZY Stock Holding History

Samlyn Capital’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,259,158
Closed -$17M – 107
2024
Q3 		$17M Sell
3,259,158
-91,377
-3% -$474K 0.26% 76
2024
Q2 		$14.9M Buy
3,350,535
+437,622
+15% +$2.12M 0.25% 81
2024
Q1 		$22.3M Sell
2,912,913
-459,645
-14% -$2.52M 0.37% 72
2023
Q4 		$14.4M Buy
3,372,558
+127,350
+4% +$452K 0.29% 68
2023
Q3 		$13.6M Buy
+3,245,208
New +$16.5M 0.22% 78

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Samlyn Capital's INZY Position: Q4 2024 in Review

Samlyn Capital sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 3,259,158 shares — an estimated $17M sold.

Samlyn Capital first reported a position in INZY in Q3 2023 and held it in 5 quarters. The position peaked at $22.3M in Q1 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Samlyn Capital reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Samlyn Capital sold 3,259,158 Inozyme Pharma shares in Q4 2024, an estimated $17M.
  • Samlyn Capital first reported a position in Inozyme Pharma in Q3 2023 and held it in 5 quarters.
  • Samlyn Capital's Inozyme Pharma position peaked at $22.3M in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Samlyn Capital's 13F filing for Q4 2024, filed 14 Feb 2025.